XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 49.05

Change

0.00 (0.00)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.50 (+0.10%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.25 (-0.49%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.29 (-0.52%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.17 (+1.13%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

+0.03 (+0.37%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

-0.14 (-0.15%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.30 (-0.13%)

USD 45.80B
0ZC:F Zscaler Inc

-0.98 (-0.50%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.69%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.16 (-0.13%)

USD 24.77B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.73% 29% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.73% 29% F 44% F
Trailing 12 Months  
Capital Gain -7.23% 18% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.23% 16% F 38% F
Trailing 5 Years  
Capital Gain 31.54% 43% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.54% 44% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 10.24% 70% C- 66% D+
Dividend Return 10.24% 68% D+ 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.74% 63% D 90% A-
Risk Adjusted Return 95.33% 88% B+ 91% A-
Market Capitalization 0.85B 72% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike